MRPL45 and medulloblastoma: It is interesting to note that few reported medulloblastoma-specific fusion peptides, such as MLLT6–MRPL45, LCLAT1–ERBB4, ASAP1–WD4HV1 and PTEN–THAP9 [2,14,15] have similar immunogenic potential to the EPC2–GULP1 fusion peptide SAEEITLTI.